Dawn of early OVERVIEW
EARLY DETECTION
THE BARRIERdetection healthcare
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2 0 2 0
OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA PARTNERSHIPS Investor Presentation T E A M
S U M M A R Y April 2021
1 Forward-Looking Information Statement also affect these forward-looking statements. The reader should not place undue Statements contained in this presentation concerning expectations, beliefs, plans, reliance on any forward-looking statements included in this presentation. These objectives, goals, strategies, future events or performance and underlying statements speak only as of the date made and Nanox is under no obligation and assumptions and other statements that are other than statements of historical fact disavows any obligation to update or revise such statements as a result of any are “forward-looking statements.” These statements often include words such as event, circumstances or otherwise, unless required by applicable legislation or “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “target,” “project,” regulation. “forecast,” “seek,” “will,” “may,” “should,” “could,” “would” or similar expressions. Although Nanox believes that the expectations and assumptions reflected in these These risks and uncertainties are described more fully under the caption ”Risk statements are reasonable, these expectations or forecasts of future performance Factors” in the Company’s registration statement relating to this offering and other may not prove to be correct. Forward-looking statements are subject to many risks filings with the Securities and Exchange Commission. Other risks and uncertainties of and uncertainties, and actual results may differ materially from the results discussed which the Company is not currently aware may also affect Company’s forward- in forward-looking statements. The following are among the important factors that looking statements. The reader should not place undue reliance on any forward- could cause actual results to differ materially from the forward-looking statements: looking statements included in this presentation. These statements speak only as of risks related to Nanox’s ability to successfully demonstrate the feasibility of its the date made and the Company is under no obligation and disavows any technology for commercial applications; Nanox’s expectations regarding the obligation to update or revise such statements as a result of any event, necessity of, timing of filing for, and receipt and maintenance of, regulatory circumstances or otherwise, unless required by applicable legislation or regulation. clearances or approvals regarding its X-Ray source technology and the Nanox.ARC from regulatory agencies worldwide and its ongoing compliance with applicable Market and Industry Data and Customer Information quality standards and regulatory requirements; Nanox’s ability to enter into and This presentation has been prepared by Nanox and includes market data and other maintain commercially reasonable arrangements with third-party manufacturers information from sources believed by the company to be reliable. For example, and suppliers to manufacture the Nanox.ARC; the market acceptance of the industry and market data, including Nanox’s own research, and surveys or industry Nanox.ARC and the proposed pay-per-scan business model; Nanox’s expectations publications and surveys as well as public information about Nanox’s customers and regarding collaborations with third-parties and their potential benefits; Nanox’s discussion with them. Some data are also based on Nanox’s good-faith estimates, ability to conduct business globally; the impact of general economic conditions, which are derived from Nanox’s review of internal sources as well as the other general conditions in the medical technology and imaging industries; the impact of sources described above. Although Nanox believes these sources are reliable, the COVID-19 pandemic on the Company's business operations; changes in the Nanox has not independently verified the information is accurate and complete. As global and regional regulatory environments in the jurisdictions in which Nanox does a result, you should be aware that market share, ranking and other similar data set or plans to do business; and market volatility, fluctuations in costs and changes to forth in this presentation, and estimates and beliefs based on such data may not be the competitive environment, among others. Consequently, actual future results reliable. may differ materially from the anticipated results expressed in the forward-looking statements. Other risks and uncertainties of which Nanox is not currently aware may
2 Nanox at a glance
The What Unmet need Game changing tech Disruptive business model
Nanox aims to build a Large deficit of medical Nanox’s novel digital X-Ray source Executed contracts for 5,150 units ILLUSTRATIVE MODEL global infrastructure for imaging systems due to high replaces an analog X-Ray that has been pending regulatory and other medical imaging system costs used for over 100 years and enables approvals POTENTIAL ANNUAL RECURRING REVENUE ASSUMING THE 5,150 significant cost reduction CONTRACTED UNITS ARE DEPLOYED AND OPERATIONAL Medical Screening as a Service $1,194,000,000 Utilizing innovative, patent (MSaaS) opens a recurring protected and disruptive Developing a new breed of medical revenue model that has the technology, Nanox can offer imaging infrastructure that can be potential to provide substantial medical technology that potentially deployed in mass due to revenues expands access, resulting in significantly lower costs and a small $397,000,000 better outcomes and lower footprint, coupled with a radiology costs. services cloud platform $139,000,000
Planning global mass 7 20 60 SCANS PER DAY Upcoming Milestones deployment of 15,000 systems with a Pay-per- Until today, technology was Scan subscription the barrier to medical model imaging availability. We are targeting several near-term value catalysts such as FDA approvals and commercialization See slide 27 for full detail and assumptions Nanox believes it has broken that barrier. Strategic partner deals signed First units shipped by Q1 2022 Concept device. Manufacturing ramp-up FDA single source and multi For educational purposes With global execution source device approvals 2/3 of the world’s population Global deployments only. expected to start this year has no meaningful access to Nanox invites partners to join medical imaging. 15,000 units the potentially next Strategic Shareholders deployed and operational revolution in Weeks and months of wait 2021 preventive healthcare. times for radiology Exceptionally seasoned execution diagnostics results. 2022-2024 team Healthcare and technology veterans from companies like GE, Philips, and highly successful, game-changing technology entrepreneurs 3 Preventive screening
OVERVIEW EARLY DETECTION Early detection is key to THE BARRIER
BREAKING THROUGH
T H E T E C H preventive healthcare.
N A N O X A R C
NANOX BENEFITS
R S N A 2020 Treatable conditions, such as cancer, cardiovascular OPINIONS failures and others are often diagnosed too late. O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
4 Early detection remains theoretical
OVERVIEW EARLY DETECTION 2/3 of the world’s THE BARRIER
BREAKING THROUGH
T H E T E C H population have no
N A N O X A R C
NANOX BENEFITS meaningful access to
R S N A 2020 OPINIONS medical imaging O U R P L A N
BUSINESS MODEL DEPLOYMENTS The majority of the remaining 1/3 suffer NANOX CLOUD from weeks and months of wait time for FDA
PARTNERSHIPS access to medical scanners and T E A M diagnostic results. S U M M A R Y
5 Why?
OVERVIEW EARLY DETECTION Medical imaging THE BARRIER
BREAKING THROUGH
T H E T E C H systems are too
N A N O X A R C NANOX BENEFITS expensive and
R S N A 2020 OPINIONS complex for mass O U R P L A N BUSINESS MODEL deployment. DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
6 The key inhibitor
OVERVIEW EARLY DETECTION X-Ray source technology THE BARRIER
BREAKING THROUGH
T H E T E C H has not changed since its
N A N O X A R C
NANOX BENEFITS discovery over 120 years
R S N A 2020 OPINIONS ago O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
7 Wilhelm Conrad Röntgen The hot cathode
OVERVIEW
EARLY DETECTION Current day X-Ray tube THE BARRIER Analog X-Ray source BREAKING THROUGH
T H E T E C H Heats up a metal filament to 2,000° Celsius to produce the N A N O X A R C electron streams necessary for NANOX BENEFITS X-Ray emission R S N A 2020
OPINIONS Electrons O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
8 Main contributor to high-cost of imaging systems
OVERVIEW
EARLY DETECTION
THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS
O U R P L A N
BUSINESS MODEL The legacy DEPLOYMENTS analog X-Ray NANOX CLOUD FDA source PARTNERSHIPS Requires extremely high-voltage, complex T E A M mechanics and special cooling to produce the S U M M A R Y electrons needed for X-Ray emission, resulting in an average $150,000 cost for the source alone 9 The Nanox paradigm
OVERVIEW
EARLY DETECTION Driving higher
THE BARRIER rates of medical BREAKING THROUGH Which we expect will prevention through T H E T E C H enable significantly early-detection. N A N O X A R C higher availability of NANOX BENEFITS Will result in lower cost R S N A 2020 imaging services A fundamental and smaller imaging OPINIONS
O U R P L A N technological systems
BUSINESS MODEL change in the X-Ray
DEPLOYMENTS source
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
10 Introducing the novel Nanox X-Ray source
OVERVIEW EARLY DETECTION Novel silicon - b a s e d , THE BARRIER BREAKING THROUGH low voltage, nano - T H E T E C H
N A N O X A R C s c a l e cold cathode
NANOX BENEFITS
R S N A 2020 Generating the electrons streams needed for X-Ray via cold field-emission technology OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA X-Ray Reimagined PARTNERSHIPS
T E A M
S U M M A R Y
11 Nanox MEMs X-Ray technology
NANOX CLEAN ROOM
• Technology originally • N a n o x manufacturing facilities (JAPAN) OVERVIEW developed by Sony and its i n J a p a n
EARLY DETECTION partners to achieve a higher quality image for screens and • Signed agreement with SK THE BARRIER m o n i t o r s Telecom for collaboration on a new Korean factory to increase BREAKING THROUGH • Sony invested substantial Nanox MEMs production T H E T E C H resources in the development of c a p a c i t y this technology for over a N A N O X A R C d e c a d e • Mature and optimized proprietary technology and NANOX BENEFITS • After acquiring the k n o w - h o w , production process with an R S N A 2020 our Japanese - Israeli team exceptionally high - y i e l d i n v e s t e d over 8 years OPINIONS • Strong IP portfolio with patents developing a source for the NANOX WAFER O U R P L A N medical imaging industry based granted in USA, Israel, Japan on this technology and pending globally BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
12 Tech transformation
OVERVIEW
EARLY DETECTION From To
THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS One metal filament heated to 2,000° Celsius 100 Million nano-cones field on a silicon T E A M requiring special cooling and rotation chip emitting digitally controlled electron S U M M A R Y mechanics streams under low voltage
13 The Nanox tube
OVERVIEW
EARLY DETECTION
THE BARRIER BREAKING THROUGH Commercially available T H E T E C H Digital X-Ray source N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS O U R P L A N The Nanox Silicon BUSINESS MODEL
DEPLOYMENTS MEMs cold cathode
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
14 The Nanox tube
OVERVIEW Significantly smaller EARLY DETECTION Substantially more cost effective THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS
O U R P L A N NANOX BUSINESS MODEL LEGACY TUBE
DEPLOYMENTS $150,000 average cost ~$100 estimated cost in mass-production NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
15 Clinical quality imaging
Nanox I kVp: 50 I mAs: 0.4 I Commercial device I kVp: 60 I mAs: 3.5
OVERVIEW
EARLY DETECTION
THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M kVp - Kilovolt Peak. kVp is the component that controls the X-Ray penetration strength and mAs - MilliAmps per Second. This parameter controls the QUANTITY or the AMOUNT
S U M M A R Y subsequently QUALITY of the X-Ray beam produced. It is also what controls the CONTRAST or of X-Ray photons produced. This is also what dictates the radiation dose. The higher GRAY SCALE in the produced X-Ray film. The Higher the kVP the LOWER the CONTRAST. the mAs the higher the radiation exposure.
16
Concept device. For educational purposes only. Clinical quality imaging
3D Image Shoulder
OVERVIEW Reconstruction
EARLY DETECTION
THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS Single slice from a reconstructed 3D T E A M tomosynthesis image that was taken during
S U M M A R Y the 2020 RSNA live demo using the Nanox.ARC
17 Concept device. For educational purposes only. NANOX X-Ray TUBE 40Kv, 2.5mA The Nanox.ARC 3D computerized tomosynthesis
OVERVIEW
EARLY DETECTION
THE BARRIER New breed of medical imaging using BREAKING THROUGH revolutionary X - r a y s o u r c e
T H E T E C H Potentially results in lower cost, less N A N O X A R C complex, and smaller imaging system NANOX BENEFITS
R S N A 2020 Aims to democratize global OPINIONS availability
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y Concept device. For educational purposes only.
18 The benefits Multi-source imaging
OVERVIEW
EARLY DETECTION
THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS NANOX CLOUD Enables simple architecture FDA Stationary sources PARTNERSHIPS Minimal moving parts T E A M Energy efficient duty-cycle S U M M A R Y Rapid digital switching 19 More clinical data Concept device. For educational purposes only. The benefits Multi-modalities
OVERVIEW
EARLY DETECTION
THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS NANOX CLOUD Single source 2D X-ray 3-Source 3D Fluoroscopy 11-Source Axial Imaging FDA
PARTNERSHIPS
T E A M
S U M M A R Y
20
Concept device. For educational purposes only. RSNA 2020
OVERVIEW • Live streaming presentation EARLY DETECTION was performed with global THE BARRIER audience of thousands BREAKING THROUGH
T H E T E C H • Nanox single source live N A N O X A R C imaging NANOX BENEFITS
R S N A 2020 • Nanox.ARC multi-source live OPINIONS imaging
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
21 RSNA 2020 Nanox single source live imaging and Nanox multi-source1 3D tomosynthesis
OVERVIEW radiologists diagnostics
EARLY DETECTION
THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD On the left - the hand of Ran Poliakine, Nanox’s CEO, as was taken On the left - single slice from a reconstructed 3D tomosynthesis image FDA during the 2020 RSNA live demo, using the Nanox single source that was taken during the 2020 RSNA live demo using the Nanox.ARC,
PARTNERSHIPS device with the Nanox tube; a multi-source device containing Nanox X-Ray tubes
T E A M On the right - the hand of Anna Bertha Ludwig, Röntgen’s wife. On the right - a single 2D plain (conventional) chest image was taken in S U M M A R Y Röntgen himself took this iconic image in 1895 a leading hospital in Israel one day before the RSNA live demo. The same phantom (w/lesions) was used for both images 22
1 Concept device. For educational purposes only. Post-RSNA Press
OVERVIEW
EARLY DETECTION
THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
23
Concept device. For educational purposes only. Our plan
OVERVIEW Disrupt the imaging market • Increase significantly medical imaging availability EARLY DETECTION • Deploy 15,000 units globally by the end of FY2024 THE BARRIER with a global service subject to Company financing, regulatory clearance BREAKING THROUGH infrastructure for medical and other contractual conditions precedent T H E T E C H • Invest CAPEX and own the systems N A N O X A R C imaging
NANOX BENEFITS • Operate a Pay-per-Scan, MSaaS business model
R S N A 2020 • Generate substantial recurring revenue stream once
OPINIONS fully deployed
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
24
Concept device. For educational purposes only. Timeline and key milestones
8 Years Q3 2020
OVERVIEW MBO by Japanese R&D Secures $79M team and investment from EARLY DETECTION establishment of Nanox; strategic investors, Manufacturing Sony and focus on medical including Foxconn, from H1 2021 THE BARRIER agreement with partners invest in imaging Industrial Alliance, Foxconn ensures Field Emission SK Telecom Ramp-up of manufacturing BREAKING THROUGH First MEMS silicon tape- manufacturing Display (FED) and systems deployments out and development quality and technology T H E T E C H of the Nanox X-Ray consistency Source N A N O X A R C Development of the Nanox.ARC Expected recurring revenue stream NANOX BENEFITS
R S N A 2020 1991 2008 2012 - 2019 2020 2021-2024 OPINIONS
O U R P L A N 2024 Sony achieves June 2019 H1 2020 H2 2020 2021 BUSINESS MODEL first FED TV Approx. 15,000 units prototype Signs 8 pre-sale Completes IPO on Strategic FDA approval of 510(k) expected to be DEPLOYMENTS agreements for NASDAQ raising $190 collaboration with FUJI submission for single deployed and deployment of thousands MM of gross proceeds source and anticipated operational globally NANOX CLOUD of units with guaranteed approval of multi-source Strategic substantial minimum Signs 1 pre-sale version collaboration with SK FDA annual service fees for at agreement with SPI for Telecom least 3 years from full deployment of 630 First commercial units PARTNERSHIPS deployment, subject to units with guaranteed expected to be regulatory and other minimum annual manufactured and T E A M clearances service fees for at least shipped to service seven years from full providers S U M M A R Y deployment
Presents its technology in a live demo at RSNA 25 Addressable market Expansion of the $21 Billion global medical imaging market through shift from CAPEX to MSaaS model OVERVIEW We do not intend to compete over market EARLY DETECTION The X-Ray-based imaging market 2021-2024
THE BARRIER Nanox addresses the market segments legacy share, we plan to expand the total market BREAKING THROUGH vendors do not traditionally sell to • We intend to sell medical imaging availability T H E T E C H • We expect to provide systems to market segments existing X-Ray vendors N A N O X A R C don’t target NANOX BENEFITS • We target Urgent Care units (over 9,600 in the US alone), outpatient clinics, R S N A 2020 Urgent Care rural areas, countries with limited medical imaging availability (e.g., India, OPINIONS units, outpatient China, Africa) clinics, nursing O U R P L A N homes etc. • We believe the CAPEX market of hospitals, medical centers and clinics will BUSINESS MODEL migrate to an OPEX service-based model over time DEPLOYMENTS • Nanox is pioneering this model today NANOX CLOUD Hospitals, • For certain medical imaging market participants, we plan to tailor our X-Ray medical imaging FDA source technology to their specific imaging systems and we expect to charge centers PARTNERSHIPS a one-time licensing fee upfront and receive recurring royalty payments for
T E A M each system sold
S U M M A R Y
26 Flexible business model to drive adoption
MSaaS Pricing model & minimum annual service fee OVERVIEW ILLUSTRATIVE MODEL • Pay-per-scan service business model EARLY DETECTION POTENTIAL ANNUAL RECURRING REVENUE ASSUMING THE 5,150 • Nanox covers CAPEX investment in systems and deployment THE BARRIER CONTRACTED UNITS ARE DEPLOYED AND OPERATIONAL • $40 total cost per scan as a global average based on current contracts $1,194,000,000 BREAKING THROUGH • Nanox revenue: $14 (out of the $40) per scan based on current contracts
T H E T E C H • Contracting regional service providers for marketing and operation of the N A N O X A R C $397,000,000 service
NANOX BENEFITS $139,000,000 • Current contracts provide a minimum annual service fee for 7 scans per
R S N A 2020 day per system against regional exclusivity 7 20 60 SCANS PER DAY
OPINIONS At 20 scans per day, and $14 per scan revenue to O U R P L A N NANOX and 23 days per month, the MSaaS model potentially generates over $397 Million in recurring BUSINESS MODEL revenues annually DEPLOYMENTS
NANOX CLOUD
FDA Scans per day - LEGEND
PARTNERSHIPS • 7 - Minimum scans per day per system • Total number of systems deployed may vary as per financing and final unit
• 20 - Nanox operational objective T E A M cost • 60 - Estimated current global average • Price-per-scan will vary based on regional economics S U M M A R Y • Minimum annual service fees will be backed by a standby letter of credit or
27 financial guarantee upon receipt of local regulatory approval Contracted deployments
Current contracts for deals - 5,150 units OVERVIEW (Pending local regulatory approval)
EARLY DETECTION • Australia, NZ, Norway - 1,000 units
• THE BARRIER Brazil - 1,000 units • Mexico and Guatemala - 630 units BREAKING THROUGH • Italy - 500 units
T H E T E C H • Russia - 500 units
N A N O X A R C • South Africa - 500 units • Taiwan, Singapore - 500 units NANOX BENEFITS • Spain - 420 units R S N A 2020 • Belarus - 100 units
OPINIONS
O U R P L A N ■ Closed pre-sale agreements Strategic Collaboration Agreements - 5,500 units BUSINESS MODEL • USA - 3,000 units
DEPLOYMENTS • Korea, Vietnam - 2,500 units
NANOX CLOUD • Units of contracted pre-sale deals, with experienced service Minimum annual service fees providers, are expected to be delivered from H2 2021 FDA Nanox current contracts require a minimum annual service • Deliveries are conditioned upon acceptance test approval fee backed by a standby letter of credit or financial PARTNERSHIPS and local and other regulatory clearance in each region guarantee upon receipt of local regulatory approval and T E A M • Active pipeline of additional countries aiming to join initial satisfaction of all conditions precedent under each
S U M M A R Y wave of deployment agreement
28 Selected customer profiles
OVERVIEW SPI Medical, S.A. de C.V. (Mexico) EARLY DETECTION
THE BARRIER • SPI Medical, S. A. de C.V. is a distributor of specialty pharma products and medical devices, operating with global leaders BREAKING THROUGH such as Abbott, Merck, Bayer and Eli Lilly, and medical T H E T E C H imaging systems from Phillips, GE, Siemens, Planmed and
N A N O X A R C Toshiba.
NANOX BENEFITS • Distributes to both the public and private sectors in Mexico
R S N A 2020 and Guatemala.
OPINIONS • Entered into an initial 7-year MSaaS agreement to distribute 1 O U R P L A N 630 Nanox Systems across Mexico and Guatemala
BUSINESS MODEL • Pursuant to the agreement $17 million2 of minimum annual
DEPLOYMENTS service fees to Nanox
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
1 29 Subject to regulatory approval and customer acceptance test 2 Assumes, per the agreement, 7 scans/day x 23 days/month x at $14 per scan x 630 units deployed Selected customer profiles
OVERVIEW Promedica Bioelectronics s.r.l. (Italy) EARLY DETECTION
THE BARRIER • Promedica Bioelectronics s.r.l. has over 25 years of experience representing diagnostic imaging vendors such BREAKING THROUGH as Fujifilm, Siemens Medical Systems and GE Healthcare T H E T E C H • Also manages commercial strategic activities for N A N O X A R C multinational companies for the marketing of systems with NANOX BENEFITS MR-guided Focused Ultrasound (InSightec) and robotic
R S N A 2020 systems for interventional radiology procedures (iSYS)
OPINIONS • Entered into an initial 4-year MSaaS agreement to distribute 1 O U R P L A N 500 Nanox Systems across Italy
BUSINESS MODEL • Pursuant to the agreement $13.5 million2 minimum annual
DEPLOYMENTS service fees to Nanox
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
1 30 Subject to regulatory approval and customer acceptance test 2 Assumes, per the agreement, 7 scans/day x 23 days/month x at $14 per scan x 500 units deployed USA
OVERVIEW EARLY DETECTION Strategic collaboration with USARAD THE BARRIER
BREAKING THROUGH • Over 250+ U.S. certified radiologists organization T H E T E C H • Providing online, remote radiology services across the U.S. N A N O X A R C • 25% owned by Siemens Healthineers NANOX BENEFITS
R S N A 2020
OPINIONS • Working with one strategic partner for nationwide deployments O U R P L A N instead of operating a large direct sales force BUSINESS MODEL • Aiming to place 3,000 systems nationwide in the next 2 years DEPLOYMENTS • Urgent care centers, primary care physicians, outpatient imaging NANOX CLOUD centers, chiropractors, veterinarians and more FDA
PARTNERSHIPS
T E A M
S U M M A R Y Once cleared by the FDA we expect the Nanox.ARC imaging procedures will be covered by radiology CPT reimbursement codes
31 The Nanox infrastructure management platform Increasing availability of medical imaging systems solves only half of the problem
OVERVIEW Purpose built proprietary radiology software platform designed to streamline operations and analytics EARLY DETECTION Radiology diagnostics remain a significant bottleneck THE BARRIER •
BREAKING THROUGH • We intend all Nanox.ARC systems to be connected to the Nanox.CLOUD T H E T E C H • A proprietary software platform designed to streamline the radiology diagnostics services and provide billing control N A N O X A R C
NANOX BENEFITS Nanox.ARC Nanox.CLOUD 3D Image Reconstruction R S N A 2020
OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
32
Concept device. For educational purposes only. A central backbone of our imaging infrastructure that we intend The Nanox.CLOUD to provide the ability to scale with connectivity to robust services
OVERVIEW • Built ground-up with automation, privacy and security in mind
EARLY DETECTION • Expected to be HIPPA and GDPR compliant
THE BARRIER • Designed to enable integration into medical systems via APIs BREAKING THROUGH • Intend to include full administrative and billing services T H E T E C H
N A N O X A R C
NANOX BENEFITS NANOX would transmit The platform would employ a
R S N A 2020 all imaging data to the matching engine to match cloud SaaS platform scans to radiologists OPINIONS
O U R P L A N Medical AI systems would provide BUSINESS MODEL first response and decision assistive DEPLOYMENTS information
NANOX CLOUD Radiology specialists would provide FDA diagnostics online
PARTNERSHIPS
T E A M Hospitals and doctors would get S U M M A R Y real-time global access
33
Concept device. For educational purposes only. Regulatory clearance
FDA OVERVIEW • We expect to take a multi-step approach to the o Plan to submit an additional 510(k) application
EARLY DETECTION regulatory clearance process: with respect to the multi-source Nanox.ARC
THE BARRIER o Submitted a 510(K) application in January 2020 and Nanox.CLOUD, which, if cleared, we
BREAKING THROUGH relating to a single source digital X-ray version expect will be our commercial imaging system of the Nanox.ARC T H E T E C H o Received an additional information request in N A N O X A R C • If cleared, we plan to deploy the first Nanox.ARC March 2020, which we responded to in units by Q4 2021 or Q1 2022 NANOX BENEFITS September 2020 R S N A 2 0 2 0 o Received an additional information request in OPINIONS January 2021 O U R P L A N o Received FDA clearance of single source BUSINESS MODEL digital x-ray version in April 2021 DEPLOYMENTS
NANOX CLOUD CE and ROW
FDA • CE submission expected in 2021
PARTNERSHIPS • Other countries will require separate submissions
T E A M
S U M M A R Y
34 Global partnerships
OVERVIEW Nanox’s cloud-based service will enable medical imaging services globally through its partnerships
EARLY DETECTION
THE BARRIER Strategic Partners AI & Image Transfer Deployments BREAKING THROUGH
T H E T E C H
N A N O X A R C 5G, MEMs manufacturing Cancer detection United States NANOX BENEFITS and APAC distribution Golden Vine Taiwan, Singapore R S N A 2020 Stroke Italy
OPINIONS Mammography OEM Russia, Belarus Chest & Head O U R P L A N Australia, Spain, New Zealand, BUSINESS MODEL Manufacturing Mammography Norway, Korea Vietnam DEPLOYMENTS Secure image transfer NANOX CLOUD Brazil, S. Africa
FDA Mexico, Guatemala PARTNERSHIPS
T E A M
S U M M A R Y
35
Concept device. For educational purposes only. A strong execution team with decades of relevant experience and proven track record of large-scale The team global projects, medical business expertise and bringing innovation to market
OVERVIEW Ran Poliakine Itzhak Maayan Jim Dara Ofir Koren CEO and Chairman of the Board Chief Financial Officer Chief Operations Officer Chief Technology Officer 36 EARLY DETECTION The founder of the wireless charging Served in financial leadership positions in Served in his last position as President of Seasoned technological leader who served industry, an entrepreneur focusing on multi-national companies including MyCharge, and prior to that as VP of as General Manager and VP R&D at ReWalk THE BARRIER global life-changing technologies and Perrigo, Cisco Systems, and Elscint. Business Development at Powermat, and VP Robotics, GM of RuggedCom, and VP R&D of inventions across multiple verticals and interim CEO at Wellsense. Alvarion. BREAKING THROUGH
T H E T E C H
N A N O X A R C Tamar Aharon Cohen Shirly Kaufman Kirshenbaum Amir Ben Shalom, Ph.D. Yoel Raab Chief Marketing Officer VP Human Resources Chief Science Officer Special Consultant NANOX BENEFITS A former medical executive at Intel and Has over a decade of experience at global Former Human Resources Director of Israeli- With over 250 patents granted and pending, Orbotech, served as Nanox CTO from corporations, serving in her last position as American Council and Regional Human Dr. Ben Shalom is a scientist, engineer, author, R S N A 2020 September 2018-January 2021, Mr. Raab CEO at Tempo-Heineken Cyprus, and prior Resources Director and HRBD EMEA and and a renowned expert in high-power analog holds a BSc. and MSc. in applied physics & to that as Division Manager at Tempo- Canada at ZIM Shipping Services Ltd. circuits and electro-optics. OPINIONS Heineken Israel. microelectronics.
O U R P L A N
BUSINESS MODEL Lydia Edwards Anat Kaphan Joon Ho Jang Hitoshi Masuya DEPLOYMENTS President, Nanox US VP Product Marketing CEO, Nanox Korea Co-Founder, Japan Laboratories Ms. Edwards has spent 3 plus decades in Past VP Product and Marketing at Mazor Mr. Jang has been in the semiconductor Mr. Masuya is a senior executive and management and leadership roles for NANOX CLOUD Robotics, and a senior executive at Philips industry for over 25 years, and has a long investor who established and led a medical and technology companies, Medical and Lumenis, Ms. Kaphan holds record of accomplishment in engineering work, number of venture capital firms, including Packard Bell, The Ensign Group, an M.B.A. in international marketing from global business development, and senior corporates and startups worldwide FDA and Nationwide Medical. Tel Aviv University. management.
PARTNERSHIPS
T E A M
S U M M A R Y
36 Advisory board
OVERVIEW
EARLY DETECTION
THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C Morry Blumenfeld Prof. Geoffrey D. Rubin Prof. Norbert Pelc Ruth Atherton, Ph.D., J,D. Dr. Rafael Grossman
NANOX BENEFITS
R S N A 2020
OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA Michael Jackman Dr. Michael Yuz Prof. Peter Dawson Prof. Yong-woo Lee Thomas Deckle PARTNERSHIPS KANGBUK SAMSUNG HOSPITAL T E A M
S U M M A R Y Professional and involved advisory board of physicians, radiologists, business veterans and global opinion 37 leaders. The Nanox advisory board is an integral part of our think-tank for product roadmap and strategy. Progress since August IPO
OVERVIEW September October January EARLY DETECTION Signs agreement with SPI Medical Announces agreement with Announces Collaborates THE BARRIER for the deployment of 630 Ambra Health to enable image with USARAD on radiology Nanox.ARC units across Mexico access to US hospitals and AI second opinion program BREAKING THROUGH and Guatemala image providers T H E T E C H
N A N O X A R C
NANOX BENEFITS R S N A 2020 2020 2021 OPINIONS
O U R P L A N
BUSINESS MODEL
DEPLOYMENTS August December January Raises gross proceeds of $190 Successfully demonstrates Nanox Announces Three Key NANOX CLOUD million through successful Nanox.ARC in a range of 2D Senior Level Hires to Support FDA initial public offering and 3D image procedures at Long-Term Growth Objectives
PARTNERSHIPS RSNA 2020
T E A M
S U M M A R Y
38 2021 Operational Goals
OVERVIEW Finalize development of the Nanox.ARC and Nanox.CLOUD systems
EARLY DETECTION
THE BARRIER Build-out of global supply chain, including chips, tubes and
BREAKING THROUGH assembly
T H E T E C H
N A N O X A R C Secure regulatory approvals in the US and other territories
NANOX BENEFITS R S N A 2020 Establish organizational infrastructure OPINIONS O U R P L A N Work with clients on deployment readiness BUSINESS MODEL DEPLOYMENTS Transform existing sales pipeline into new sales agreements NANOX CLOUD
FDA Expand partnership network PARTNERSHIPS
T E A M
S U M M A R Y
39 Summary
OVERVIEW • Nanox is developing a digital source x-ray • We believe that the industry should migrate to an technology enabling a new generation of imaging open platform “App Store” model with multiple EARLY DETECTION devices that could significantly reduce the costs of diagnostics support applications to choose from THE BARRIER medical imaging systems instead of a one “walled-off” software package
BREAKING THROUGH • Allows for multi-source scanning due to the low cost • We believe medical imaging should migrate to a T H E T E C H of the x-ray source – which opens the door for universally-connected, global cloud service with N A N O X A R C innovative imaging systems and improved clinical superior accessibility to medical data and its analysis
NANOX BENEFITS value for diagnostics (in conformance with all applicable privacy laws) for the benefit of preventive healthcare and global R S N A 2020 • Aiming to significantly increase medical imaging health analytics and studies availability and affordability worldwide OPINIONS • We plan to proactively promote our business plan via O U R P L A N • We believe the industry should shift to a service deployment of 15,000 units globally by year end 2024 and through partnerships BUSINESS MODEL based, pay-per-scan (MSaaS) business model vs. the
DEPLOYMENTS legacy capital investment model
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
40
Concept device. For educational purposes only. OVERVIEW
EARLY DETECTION
THE BARRIER
BREAKING THROUGH
T H E T E C H
N A N O X A R C
NANOX BENEFITS
R S N A 2020
OPINIONS O U R P L A N Thank You BUSINESS MODEL
DEPLOYMENTS
NANOX CLOUD
FDA
PARTNERSHIPS
T E A M
S U M M A R Y
41